Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 5/20 | 1.00 |
| ▸ | MPI | P34949 | 2/20 | 0.59 |
| ▸ | PHOSPHO1 | Q8TCT1 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | QSOX1 | O00391 | 1/20 | 0.59 |
| ▸ | RGS12 | O14924 | 1/20 | 0.59 |
| ▸ | PMM2 | O15305 | 1/20 | 0.59 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.59 |
| ▸ | GMNN | O75496 | 1/20 | 0.59 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | CYBB | P04839 | 1/20 | 0.59 |
| ▸ | BCHE | P06276 | 1/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10501611 | 0.79 | METAP2 (0.66) | METAP2MPIPHOSPHO1KDM4EMEN1 | |
| SCHEMBL29261063 | 0.79 | METAP2 (0.66) | METAP2MPIPHOSPHO1KDM4EMEN1 | |
| SCHEMBL30530466 | 0.79 | METAP2 (0.66) | METAP2MPIPHOSPHO1KDM4EMEN1 | |
| SCHEMBL10501917 | 0.79 | METAP2 (0.68) | METAP2MPIPHOSPHO1KDM4EMEN1 | |
| SCHEMBL10501672 | 0.79 | MPI (0.72) | METAP2MPIPHOSPHO1KDM4EMEN1 | |
| SCHEMBL30988556 | 0.79 | METAP2 (0.65) | METAP2MPIPHOSPHO1KDM4EMEN1 | |
| SCHEMBL10873365 | 0.79 | METAP2 (0.65) | METAP2MPIPHOSPHO1KDM4EMEN1 | |
| SCHEMBL28618904 | 0.78 | METAP2 (0.64) | METAP2MPIPHOSPHO1KDM4EMEN1 | |
| SCHEMBL10956493 | 0.77 | METAP2 (0.62) | METAP2MPIPHOSPHO1KDM4EMEN1 | |
| SCHEMBL5916623 | 0.76 | METAP2 (0.61) | METAP2MPIPHOSPHO1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190142801-A1 | USE OF SMALL MOLECULES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE TOXICITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2019-05-16 | — | — | US | disclosed |
| US-10172829-B2 | Use of small molecules for the treatment of clostridium difficile toxicity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170128420-A1 | USE OF SMALL MOLECULES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE TOXICITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-05-11 | — | — | US | disclosed |
| EP-0198277-B1 | DISELENO-BIS-BENZAMIDES OF PRIMARY AND SECONDARY AMINES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | A. Nattermann & Cie. GmbH (DE) | 1989-05-03 | — | — | EP | disclosed |
| EP-0198277-A1 | Diseleno-bis-benzamides of primary and secondary amines, processes for their production and pharmaceutical preparations containing them | A. Nattermann & Cie. GmbH (DE) | 1986-10-22 | — | — | EP | disclosed |
| EP-0044453-B1 | NEW BENZISOSELENAZOLONES, PROCESS FOR PRODUCING THE SAME AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | A. Nattermann & Cie. GmbH (DE) | 1984-04-11 | — | — | EP | disclosed |
| US-4418069-A | Benzisoselenazolones and process for the treatment of rheumatic and arthritic diseases using them | A. NATTERMANN & CIE GMBH (DE) | 1983-11-29 | — | — | US | disclosed |
| EP-0044453-A2 | New benzisoselenazolones, process for producing the same and pharmaceutical preparations containing the same | A. Nattermann & Cie. GmbH (DE) | 1982-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172829-B2 | Use of small molecules for the treatment of clostridium difficile toxicity | SLC10A2, TCERG1, SBDS | METAP2 1571/4885MPI 4658/4885PHOSPHO1 2163/4885 |
| US-20190142801-A1 | USE OF SMALL MOLECULES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE TOXICITY | SLC10A2, TCERG1, SBDS | METAP2 1571/4885MPI 4658/4885PHOSPHO1 2163/4885 |
| US-20170128420-A1 | USE OF SMALL MOLECULES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE TOXICITY | SLC10A2, TCERG1, SBDS | METAP2 1571/4885MPI 4658/4885PHOSPHO1 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.